FDA Staff Flag Reaction Risk With AstraZeneca PLC’s RSV Drug Motavizumab

WASHINGTON -(Dow Jones)- U.S. Food and Drug Administration staff said they are concerned about the risk for serious allergic reactions with a proposed AstraZeneca PLC (AZN) drug designed to prevent a respiratory infection in pre- term babies.